The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular ...

The FDA has approved Dupixent as the first new targeted therapy in over ten years for chronic spontaneous urticaria in patients aged 12 and older who remain symptomatic despite antihistamine treatment ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden ...

Type 2 diabetes is often ... fuels on organs and tissues, enhanced inflammatory signalling, and activation of endoplasmic reticulum (ER) stress pathways. Different tissues respond to excess ...

Eliminated the link between adipose tissue inflammation induced by LDL, or other metabolic and microbial inflammatory triggers, with several risk factors for type 2 diabetes and cardiovascular ...

In the search for better ways to treat diabetes, researchers at the University of Geneva have uncovered a promising new ...

However, new research from Washington University School of Medicine in St. Louis has identified a specific brain pathway that directly links cancer-related inflammation to a drop in motivation.

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Researchers identified a direct connection between cancer-related inflammation and the loss of motivation characteristic of advanced cancer. In a mouse study, they describe a brain pathway that starts ...